mutant CXCR3 ligand-immunoglobulin fusion protein (JYANT Technologies)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemutant CXCR3 ligand-immunoglobulin fusion protein (JYANT Technologies)
Drug Alias Namemut-CXCL11-IgCXCR3 biologic antagonist (JYANT Technologies)
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionC-X-C motif chemokine receptor 3 antagonists
TargetsC-X-C motif chemokine receptor 3
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJyant Technologies
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJyant Technologies
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A